Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review
- PMID: 32520664
- PMCID: PMC7307670
- DOI: 10.1089/wound.2019.0977
Toxic Epidermal Necrolysis and Steven-Johnson Syndrome: A Comprehensive Review
Abstract
Significance: Toxic epidermal necrolysis (TEN) and Steven-Johnson syndrome (SJS) are potentially fatal acute mucocutaneous vesiculobullous disorders. Evidence to date suggests that outcomes for patients with both TEN and SJS are largely dependent on stopping the causative agent, followed by supportive care and appropriate wound management in a specialized burns unit. These are life-threatening conditions characterized by widespread full-thickness cutaneous and mucosal necrosis. This article outlines the approach to holistic management of such patients, in a specialized unit, highlighting various practical aspects of wound care to prevent complications such as infection, mucosal and adhesions, and ocular scaring. Recent Advances: There is improved understanding of pain and morbidity with regard to the type and frequency of dressing changes. More modern dressings, such as nanocrystalline, are currently favored as they may be kept in situ for longer periods. The most recent evidence on systemic agents, such as corticosteroids and cyclosporine, and novel treatments, are also discussed. Critical Issues: Following cessation of the culprit trigger, management in a specialized burns unit is the most important management step. It is now understood that a multidisciplinary team is essential in the care of these patients. Following admission of such patients, dermatology, ear, nose, and throat surgery, ophthalmology, urology, colorectal surgery, and gynecology should all be consulted to prevent disease sequelae. Future Directions: Looking forward, research is aimed at achieving prospective data on the efficacy of systemic immunomodulating agents and dressing types. Tertiary centers with burns units should develop policies for such patients to ensure that the relevant teams are consulted promptly to avoid mucocutaneous complications.
Keywords: Steve–Johnson syndrome; drug reaction; toxic epidermal necrolysis.
Conflict of interest statement
C.J. and A.C. have shares in a company with an interest in a variant of activated protein C to treat diabetic wounds. No other competing financial interests exist.
None of the other authors has any disclosures. The content of this article was expressly written by the authors listed. No ghostwriters were used to write this article.
Figures
Similar articles
-
Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results.Burns. 2018 Jun;44(4):807-815. doi: 10.1016/j.burns.2017.10.022. Epub 2018 Apr 4. Burns. 2018. PMID: 29627131 Review.
-
Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience.Burns. 2017 Feb;43(1):200-205. doi: 10.1016/j.burns.2016.07.026. Epub 2016 Aug 21. Burns. 2017. PMID: 27554629
-
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.Clin Rev Allergy Immunol. 2018 Feb;54(1):147-176. doi: 10.1007/s12016-017-8654-z. Clin Rev Allergy Immunol. 2018. PMID: 29188475 Review.
-
Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience.Burns. 2018 May;44(3):603-611. doi: 10.1016/j.burns.2017.09.015. Epub 2017 Oct 10. Burns. 2018. PMID: 29029855
-
Stevens-Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unit.J Wound Care. 2021 Jun 2;30(6):492-496. doi: 10.12968/jowc.2021.30.6.492. J Wound Care. 2021. PMID: 34121430
Cited by
-
Trastuzumab-induced toxic epidermal necrolysis in a Her-2-positive metastatic breast cancer patient-A rare case report.Clin Case Rep. 2024 Jun 23;12(7):e9103. doi: 10.1002/ccr3.9103. eCollection 2024 Jul. Clin Case Rep. 2024. PMID: 38915931 Free PMC article.
-
Pembrolizumab-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in a Vietnamese patient with nonsmall-cell lung cancer.Asia Pac Allergy. 2024 Jun;14(2):84-89. doi: 10.5415/apallergy.0000000000000131. Epub 2023 Dec 18. Asia Pac Allergy. 2024. PMID: 38827262 Free PMC article.
-
A case of sodium bromfenac eye drop-induced toxic epidermal necrolysis and literature review.Arch Dermatol Res. 2024 May 11;316(5):167. doi: 10.1007/s00403-024-02914-4. Arch Dermatol Res. 2024. PMID: 38734855 Review. No abstract available.
-
Idiopathic toxic epidermal necrolysis in a pediatric patient.Proc (Bayl Univ Med Cent). 2024 Feb 8;37(2):336-338. doi: 10.1080/08998280.2024.2301782. eCollection 2024. Proc (Bayl Univ Med Cent). 2024. PMID: 38343491 Free PMC article.
-
Lamotrigine-associated toxic epidermal necrolysis.Pak J Med Sci. 2023 Nov-Dec;39(6):1883-1886. doi: 10.12669/pjms.39.6.7513. Pak J Med Sci. 2023. PMID: 37936783 Free PMC article.
References
-
- Bastuji-Garin S, Fouchard N, Bertocchi M, et al. . SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–153 - PubMed
-
- Rzany B, Mockenhaupt M, Baur S, et al. . Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49:769. - PubMed
-
- Strom BL, Carson JL, Halpern AC, et al. . Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med 1991;10:565. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
